Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2023 14:31 ET | Source: Spark Biomedical

Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults

DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
July 06, 2023 14:37 ET | Source: Spark Biomedical

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

DALLAS, TX and MANHASSET, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Five Liters, a Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to...
January 17, 2023 12:47 ET | Source: Spark Biomedical

Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal

GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
June 02, 2022 11:00 ET | Source: Spark Biomedical

Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss

DALLAS, TX and MANHASSET, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation solutions, announced today a collaboration with The Feinstein Institutes for...
March 03, 2022 11:22 ET | Source: Spark Biomedical

Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome

Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
November 16, 2021 11:00 ET | Source: Spark Biomedical

Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment

Dallas, TX, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. has been helping patients overcome acute opioid withdrawal using its Sparrow Therapy System — Transcutaneous Auricular...
November 04, 2021 10:25 ET | Source: Spark Biomedical

Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients

Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....
May 26, 2021 11:19 ET | Source: Spark Biomedical

Sierra Tucson Combats Opioid Withdrawal Using Groundbreaking Wearable Neurostimulation Therapy

TUCSON, AZ, May 26, 2021 (GLOBE NEWSWIRE) -- Sierra Tucson, a nationally respected provider of comprehensive residential services for adults struggling with substance use disorders and other...
February 03, 2021 15:34 ET | Source: Spark Biomedical

Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System

Danville, KY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Dr. Anjum Bux, a leading expert in pain management, was the first in the nation to successfully treat commercial patients using Transcutaneous...
January 04, 2021 16:38 ET | Source: Spark Biomedical

Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults

Dallas, TX, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to The Sparrow Therapy System, a...